Company intelligence / Profile preview

iCarbonX

Shenzhen, Guangdong, China

Ownership: Private
Employees: ~150
Development stage: Other

Overview

iCarbonX has built a large-scale AI-powered multiomics platform to integrate biological big data for personalized healthcare. The company supports partners in disease prevention, diagnosis, treatment innovation, next-generation diagnostics development, vaccine R&D acceleration, and biomedicine. No clinical trial results are reported as the company does not directly develop therapeutics. Its main achievement has been the creation of an advanced digital ecosystem that enables individualized care through massive datasets analyzed by artificial intelligence.

Therapeutic areas: OtherInfectious Diseases
Modalities: Data analytics platform (multi-modal omics data)Artificial intelligence-driven health management solutions
Industry: Drug Discovery Services

Partnerships

Tencent HoldingsVcanbio Cell & Gene Engineering Corp. ("VCANBIO")

Beyond the preview

Go deeper on iCarbonX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iCarbonX.

Explore the full profile